Overall, obesity-associated endocrine deregulation marked by alterations in adiponectin, leptin, insulin, IGF1 and estrogens contributes to increased risk of cancer progression and recurrence in obese breast cancer patients. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.